Relmada Therapeutics Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los beneficios de Relmada Therapeutics disminuyan a un ritmo anual de 10.7%, mientras que sus ingresos anuales crecerán a un ritmo de 55.8% por año. Se espera que el BPA crezca en un 7.4% al año.
Información clave
-10.7%
Tasa de crecimiento de los beneficios
7.35%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 11.9% |
| Tasa de crecimiento de los ingresos | 55.8% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 13 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Nueva narrativa • Mar 20
Phase III Bladder Cancer Catalyst Will Drive Long Term Value For This Biotech
Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company focused on developing NDV-01 for non muscle invasive bladder cancer and sepranolone for compulsivity related neurological disorders. What are the underlying business or industry changes driving this perspective?
Nueva narrativa • Mar 05
Bladder Cancer And Compulsive Disorder Therapies Will Support A Stronger Long Term Outlook
Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company developing NDV-01 for non muscle invasive bladder cancer and sepranolone for compulsive behavior disorders such as Prader Willi syndrome. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Mar 21
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Summary RLMD plans to report results from the phase 3 Reliance II study of REL-1017, as an adjunctive treatment for major depressive disorder, in H2 2024. The current timeline for completion of enrolment in Reliance II may suggest a slight slippage, but my position on the potential for a run up is unchanged. RLMD notes it has cash to complete its current studies Reliance II and Relight, as well as a phase 1 study of modified release psilocybin. Read the full article on Seeking AlphaArtículo de análisis • Mar 13
Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Jan 14
Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark
Summary Relmada Therapeutics is developing REL-1017, a therapy for CNS diseases that targets hyperactive GluN2D channels in NMDA receptors. Phase 2 trial showed a rapid and sustained antidepressant effect in patients who did not respond to standard antidepressants. Phase 3 trial missed its primary endpoint, but post-hoc analysis showed a robust difference between REL-1017 and placebo when excluding certain clinical sites. Read the full article on Seeking AlphaArtículo de análisis • Dec 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Artículo de análisis • Aug 29
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Artículo de análisis • May 07
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Artículo de análisis • Dec 15
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Oct 14
Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure
Truist and Guggenheim have downgraded Relmada Therapeutics (NASDAQ:RLMD) to hold and neutral, respecitvely, following the failure of phase 3 depression REL-1017. Truist lowered its price target to $10 from $90 (~54% upside based on Thursday's close) while Guggenheim doesn't have a target. Truist analyst Joon Lee wrote that based on conversations with key opinion leaders, REL-1017 would have faced headwinds on approval due to a REMS requirement and DEA scheduling. Guggenheim is removing its sales estimated for REL-1017. Analyst Yatin Suneja wrote that Relmada could still salvage the candidate by either adding substantially more participants to the RELIANCE 1 trial or persuade regulators to exclude patients from the handful of sites where a high placebo effect was observed. However, Suneja conceded the second option is less likely. Seeking Alpha's Quant Rating views Relmada (RLMD) as a hold with high marks for momentum and growth.Seeking Alpha • Sep 14
Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up
Summary We initiate Relmada Therapeutics with a Strong BUY rating due to our high degree of conviction on REL-1017's clinical success during the phase 3 trial. The phase 2 data showed that REL-1017 is rapid, effective, safe, and durable. Looking at the robust mechanism of action and phase 2 clinical data, we believe the clinical data to hold in phase 3. The key catalyst is REL-1017's phase 3 data that is expected in Q4 22 which we believe will move the stock price substantially and we are planning to start establishing a small option-sized position of the ticker. Background Relmada Therapeutics (NASDAQ:RLMD) is a US-based, pre-commercial stage biotech developing therapies for depressive disorders. The company is trading at a 700M enterprise value and holds 200M cash, which is a highly robust cash runway for a clinical-stage company. Accordingly, we initiate RLMD with a strong BUY rating. RLMD IR deck (RLMD IR deck) The unique mechanism of action of REL-1017 is key for best-in-class efficacy and safety REL-1017 is a novel first-in-class compound formulation of oral dextromethadone currently being studied to target depressive disease. We highlight that REL-1017 is the only compound that uniquely targets NMDA receptors to treat depression. The drug's key compositions are dextromethadone, the purified "d" enantiomer of methadone. We note that this is important for the drug's exceptional safety, a racemic mixture of "d" and "l" methadone is currently used to treat patients with opioid addiction problems; however, the "d" form lacks substantial opioid receptor activity and instead works as an NMDA receptor antagonist and channel blocker, similar to ketamine. Phase 2 efficacy and safety data points were effective and clean, we are optimistic about the success of the drug in phase 3 We highlight the key takeaways from phase 2 trials i) effective and durable anti-depressant effects on all tested scales, ii) rapid onset of action, with detected efficacy by day 4, iii) robust safety without opioid-related adverse events, psychotomimetic adverse events, and metabolic side-effects were shown, and iv) convenience - the drug is orally administered with a QD tablet formulation. RLMD IR deck (RLMD IR deck) Key findings are: Subjects in both the REL-1017 25 mg and 50 mg treatment groups experienced statistically significant improvement of their depression compared to subjects in the placebo group on all efficacy measures, including: the MADRS; the Clinical Global Impression – Severity (CGI-S) scale; the Clinical Global Impression – Improvement (CGI-I) scale; and the Symptoms of Depression Questionnaire (SDQ). The improvement on the MADRS appeared on Day 4 in both REL-1017 dose groups and continued through Day 7 and Day 14, seven days after treatment discontinuation, with p-values <0.03 and large effect sizes (a measure of quantifying the difference between two groups), ranging from 0.7 to 1.0. Similar findings emerged from the CGI-S and CGI-I scales. Source: company IR deck We believe REL-1017's remarkable potency combined with the drug's rapid and sustained effects make it the best-in-class agent currently being developed. We highlight that REL-1017 demonstrated impressive separation from placebo on the MADRS endpoint on Day 14. In comparison to SOCs, the ~9.4–10.4 reduction compared to placebo is more than double the reduction seen with approved anti-depressants. This level of efficacy was achieved in a more challenging, treatment-refractory patient population, which is highly promising moving forward in terms of commercial potential. Keeping the difference in study design in mind, if we compare REL-1017 to fellow NMDA receptor antagonists, Spravato, Spravato only demonstrated a 4.0 reduction in MADRS score over placebo at day 28 in its pivotal TRANSFORM-2 trial. RLMD IR deck (RLMD IR deck) RLMD IR deck (RLMD IR deck) as shown above (REL-1017 phase 2 study safety data (Company IR) No serious treatment-emergent adverse events were shown. In terms of safety, the global safety profile seems superior to Spravato as there were no reported dissociative/psychomimetic effects. Furthermore, there were no signs of opioid withdrawal upon treatment discontinuation. The most common adverse events included mild to moderate headache, nausea, and sedation, which were evenly distributed across the treatment arms, which does not concern us, and we believe the drug has a robust profile with a favorable risk/benefit as an MDD therapeutic candidate. Furthermore, we believe REL-1017's oral formulation to be more convenient for patients than Spravato's intranasal administration as it is less discrete. We believe the phase 3 trial design is robust and the endpoints are achievable for the drug based on their robust phase 2 performanceSeeking Alpha • Aug 09
Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression
Relmada Therapeutics (NASDAQ:RLMD) said on Tuesday the U.S. Food and Drug Administration had granted Fast Track designation to its drug, REL-1017, as a monotherapy to treat major depressive disorder. (RLMD) rose 3.3% premarket. For a fast track drug, the company must show some advantage over current therapy, such as superior effectiveness, effect on serious outcomes or improved effect on serious outcomes, and avoiding serious side effects of an available therapy. A drug that receives Fast Track designation is eligible for Accelerated Approval and Priority Review.Artículo de análisis • Jul 14
We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Artículo de análisis • Feb 26
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Jan 28
4 Clinical Catalysts On Tap For Relmada In 2022
RLMD is set to produce results in 2022 from four clinical trials of REL-1017, its novel antidepressant. Late-stage failures of antidepressants are not unheard of, so I provide a cautionary tale to RLMD longs. The timing of readouts allows for an interesting potential trade, avoiding exposure to an earlier study which I feel has more downside than upside potential.Artículo de análisis • Nov 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Seeking Alpha • Jun 28
Our First Look At Relmada Therapeutics
Relmada Therapeutics, Inc.’s (RLMD) sole clinical asset, oral antidepressant therapy esmethadone, is undergoing two pivotal trials for the treatment of MDD. Phase 2 study data demonstrate a rapid onset of action that no other currently approved oral therapy can boast. Despite esmethadone’s promise, Axsome Therapeutics (AXSM) has a similar oral candidate (AXS-05) with a novel MOA and August 22nd, 2021 PDUFA date, suggesting an ~18-month head start. A full investment analysis is presented in the paragraphs below.Artículo de análisis • Jun 28
We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • Mar 09
Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • Jan 15
What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?
If you want to know who really controls Relmada Therapeutics, Inc. ( NASDAQ:RLMD ), then you'll have to look at the...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 38 | -121 | -77 | -113 | 1 |
| 12/31/2027 | N/A | -109 | -36 | -89 | 5 |
| 12/31/2026 | N/A | -82 | -30 | -76 | 5 |
| 3/31/2026 | N/A | -59 | -43 | -43 | N/A |
| 12/31/2025 | N/A | -57 | -46 | -46 | N/A |
| 9/30/2025 | N/A | -56 | -40 | -40 | N/A |
| 6/30/2025 | N/A | -68 | -50 | -50 | N/A |
| 3/31/2025 | N/A | -76 | -57 | -57 | N/A |
| 12/31/2024 | N/A | -80 | -52 | -52 | N/A |
| 9/30/2024 | N/A | -86 | -53 | -53 | N/A |
| 6/30/2024 | N/A | -87 | -48 | -48 | N/A |
| 3/31/2024 | N/A | -94 | -48 | -48 | N/A |
| 12/31/2023 | N/A | -99 | -52 | -52 | N/A |
| 9/30/2023 | N/A | -112 | -77 | -77 | N/A |
| 6/30/2023 | N/A | -129 | -93 | -93 | N/A |
| 3/31/2023 | N/A | -144 | -101 | -101 | N/A |
| 12/31/2022 | N/A | -157 | -104 | -104 | N/A |
| 9/30/2022 | N/A | -153 | -106 | -106 | N/A |
| 6/30/2022 | N/A | -157 | -100 | -100 | N/A |
| 3/31/2022 | N/A | -143 | -95 | -95 | N/A |
| 12/31/2021 | N/A | -126 | -92 | -92 | N/A |
| 9/30/2021 | N/A | -112 | -61 | -61 | N/A |
| 6/30/2021 | N/A | -86 | -53 | -53 | N/A |
| 3/31/2021 | N/A | -71 | -40 | -40 | N/A |
| 12/31/2020 | N/A | -59 | -28 | -28 | N/A |
| 9/30/2020 | N/A | -43 | -25 | -25 | N/A |
| 6/30/2020 | N/A | -30 | -15 | -15 | N/A |
| 3/31/2020 | N/A | -23 | -14 | -14 | N/A |
| 12/31/2019 | N/A | -15 | N/A | -12 | N/A |
| 9/30/2019 | N/A | -18 | N/A | -11 | N/A |
| 6/30/2019 | N/A | -17 | N/A | -10 | N/A |
| 3/31/2019 | N/A | -17 | N/A | -9 | N/A |
| 12/31/2018 | N/A | -17 | N/A | -9 | N/A |
| 9/30/2018 | N/A | -11 | N/A | -7 | N/A |
| 6/30/2018 | N/A | -9 | N/A | -6 | N/A |
| 3/31/2018 | N/A | -7 | N/A | -5 | N/A |
| 12/31/2017 | N/A | -6 | N/A | -5 | N/A |
| 9/30/2017 | N/A | -6 | N/A | -5 | N/A |
| 6/30/2017 | N/A | -6 | N/A | -6 | N/A |
| 3/31/2017 | N/A | -8 | N/A | -8 | N/A |
| 12/31/2016 | N/A | -8 | N/A | -10 | N/A |
| 9/30/2016 | N/A | -9 | N/A | -12 | N/A |
| 6/30/2016 | N/A | -3 | N/A | -13 | N/A |
| 3/31/2016 | N/A | 6 | N/A | -15 | N/A |
| 12/31/2015 | N/A | 6 | N/A | -16 | N/A |
| 9/30/2015 | N/A | 14 | N/A | -17 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que RLMD siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que RLMD siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que RLMD siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que RLMD no tenga ingresos el año que viene.
Ingresos de alto crecimiento: Se prevé que RLMD no tenga ingresos el año que viene.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de RLMD se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/14 20:36 |
| Precio de las acciones al final del día | 2026/05/14 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Relmada Therapeutics, Inc. está cubierta por 10 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Maxim Jacobs | Edison Investment Research |
| Farzin Haque | Jefferies LLC |
| Andrew Berens | Leerink Partners LLC |